SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

KURA

Kura Oncology, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong efficacy data in frontline AML supports ziftomenib's potential label expansion, which could significantly increase peak sales. Monitor EHA 2026 presentation on June 14 for updated durability and safety data, and the virtual investor call on June 3 for additional context. The Phase 3 KOMET-017 enrollment progress will be a key catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.68
T+0 close · May 12, 2026 · via day close
Latest settled
−4.13%
T+60 · $9.28
Vs SPY
−8.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $9.68entry
  2. T+1 · 6mo ago −2.07%α −2.64% · $9.48
  3. T+5 · 6mo ago −4.96%α −5.04% · $9.20
  4. T+20 · 5mo ago −10.33%α −8.60% · $8.68
  5. T+60 · 3mo ago −4.13%α −8.52% · $9.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be presented at EHA 2026. The 99-patient dataset shows high CRc rates (90-96%) and deep MRD negativity (>80%) across NPM1-m and KMT2A-r subtypes, with median duration of CRc not reached in NPM1-m patients at ~15 months follow-up. The Phase 3 KOMET-017 trial is enrolling, with potential for accelerated FDA review in 2028.

Key Facts

  • Oral presentation at EHA 2026 on June 14 will feature 99-patient dataset with extended follow-up
  • CRc rates: 96% (NPM1-m) and 90% (KMT2A-r) in frontline AML
  • MRD-negativity rates: 83% (NPM1-m) and 82% (KMT2A-r) among CRc responders
  • Median duration of CRc not reached in NPM1-m at 14.9 months median follow-up
  • Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028
  • Ziftomenib already FDA-approved as KOMZIFTI for R/R NPM1-m AML

Financial Impact

No financial figures disclosed; potential to expand ziftomenib's addressable market from R/R to frontline AML, which represents a larger patient population

revenuemarket share

Risk Factors

  • Differentiation syndrome remains a boxed warning risk (26% incidence in R/R AML)
  • Phase 3 KOMET-017 trial may fail to replicate Phase 1 results
  • Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
  • Potential for accelerated FDA review in 2028 is aspirational and not guaranteed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293020

Track record

29 reports on KURA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026